nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2C8—Cyclosporine—focal segmental glomerulosclerosis	0.16	0.332	CbGbCtD
Paroxetine—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.112	0.232	CbGbCtD
Paroxetine—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.109	0.225	CbGbCtD
Paroxetine—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.102	0.212	CbGbCtD
Paroxetine—Gingival hyperplasia—Cyclosporine—focal segmental glomerulosclerosis	0.00939	0.0216	CcSEcCtD
Paroxetine—Salivary gland enlargement—Cyclosporine—focal segmental glomerulosclerosis	0.00911	0.021	CcSEcCtD
Paroxetine—Toxicity to various agents—Cyclosporine—focal segmental glomerulosclerosis	0.00885	0.0204	CcSEcCtD
Paroxetine—Rheumatoid arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00838	0.0193	CcSEcCtD
Paroxetine—Carcinoma—Cyclosporine—focal segmental glomerulosclerosis	0.00838	0.0193	CcSEcCtD
Paroxetine—Goitre—Cyclosporine—focal segmental glomerulosclerosis	0.00708	0.0163	CcSEcCtD
Paroxetine—Stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.00665	0.0153	CcSEcCtD
Paroxetine—Pancreatitis acute—Cyclosporine—focal segmental glomerulosclerosis	0.00548	0.0126	CcSEcCtD
Paroxetine—Leukorrhea—Cyclosporine—focal segmental glomerulosclerosis	0.00539	0.0124	CcSEcCtD
Paroxetine—Trauma—Cyclosporine—focal segmental glomerulosclerosis	0.00531	0.0122	CcSEcCtD
Paroxetine—Nephropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00531	0.0122	CcSEcCtD
Paroxetine—Muscle contractions involuntary—Cyclosporine—focal segmental glomerulosclerosis	0.00523	0.012	CcSEcCtD
Paroxetine—Bursitis—Cyclosporine—focal segmental glomerulosclerosis	0.00523	0.012	CcSEcCtD
Paroxetine—Myositis—Cyclosporine—focal segmental glomerulosclerosis	0.00516	0.0119	CcSEcCtD
Paroxetine—Ear disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00469	0.0108	CcSEcCtD
Paroxetine—Urine abnormality—Cyclosporine—focal segmental glomerulosclerosis	0.00457	0.0105	CcSEcCtD
Paroxetine—Micturition urgency—Cyclosporine—focal segmental glomerulosclerosis	0.00446	0.0102	CcSEcCtD
Paroxetine—Gingival bleeding—Cyclosporine—focal segmental glomerulosclerosis	0.00446	0.0102	CcSEcCtD
Paroxetine—Hirsutism—Cyclosporine—focal segmental glomerulosclerosis	0.00435	0.01	CcSEcCtD
Paroxetine—Multiple fractures—Cyclosporine—focal segmental glomerulosclerosis	0.00435	0.01	CcSEcCtD
Paroxetine—Gastric ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00435	0.01	CcSEcCtD
Paroxetine—Fracture—Cyclosporine—focal segmental glomerulosclerosis	0.00435	0.01	CcSEcCtD
Paroxetine—Cerebration impaired—Cyclosporine—focal segmental glomerulosclerosis	0.0043	0.00989	CcSEcCtD
Paroxetine—Urine analysis abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.0043	0.00989	CcSEcCtD
Paroxetine—Libido increased—Cyclosporine—focal segmental glomerulosclerosis	0.00416	0.00956	CcSEcCtD
Paroxetine—Vaginal discharge—Cyclosporine—focal segmental glomerulosclerosis	0.00416	0.00956	CcSEcCtD
Paroxetine—Optic neuritis—Cyclosporine—focal segmental glomerulosclerosis	0.00411	0.00945	CcSEcCtD
Paroxetine—Tooth disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0039	0.00897	CcSEcCtD
Paroxetine—Peptic ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00378	0.0087	CcSEcCtD
Paroxetine—Menstrual disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00371	0.00853	CcSEcCtD
Paroxetine—Myopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00361	0.00829	CcSEcCtD
Paroxetine—Thrombosis—Cyclosporine—focal segmental glomerulosclerosis	0.00357	0.00822	CcSEcCtD
Paroxetine—Tongue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00348	0.008	CcSEcCtD
Paroxetine—Herpes zoster—Cyclosporine—focal segmental glomerulosclerosis	0.00336	0.00772	CcSEcCtD
Paroxetine—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00325	0.00747	CcSEcCtD
Paroxetine—Hyperaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00322	0.00741	CcSEcCtD
Paroxetine—Gingivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00322	0.00741	CcSEcCtD
Paroxetine—Abscess—Cyclosporine—focal segmental glomerulosclerosis	0.0032	0.00735	CcSEcCtD
Paroxetine—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.00301	0.00691	CcSEcCtD
Paroxetine—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.00296	0.00681	CcSEcCtD
Paroxetine—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.00292	0.00671	CcSEcCtD
Paroxetine—Breast pain—Cyclosporine—focal segmental glomerulosclerosis	0.0029	0.00667	CcSEcCtD
Paroxetine—Amenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00288	0.00662	CcSEcCtD
Paroxetine—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.00282	0.00648	CcSEcCtD
Paroxetine—Rectal haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.0028	0.00644	CcSEcCtD
Paroxetine—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00278	0.0064	CcSEcCtD
Paroxetine—Dysmenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00278	0.0064	CcSEcCtD
Paroxetine—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00278	0.0064	CcSEcCtD
Paroxetine—Arthropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00278	0.0064	CcSEcCtD
Paroxetine—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.00274	0.00631	CcSEcCtD
Paroxetine—Glossitis—Cyclosporine—focal segmental glomerulosclerosis	0.00274	0.00631	CcSEcCtD
Paroxetine—Nocturia—Cyclosporine—focal segmental glomerulosclerosis	0.00273	0.00627	CcSEcCtD
Paroxetine—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.00271	0.00623	CcSEcCtD
Paroxetine—Cataract—Cyclosporine—focal segmental glomerulosclerosis	0.00266	0.00611	CcSEcCtD
Paroxetine—Hiccups—Cyclosporine—focal segmental glomerulosclerosis	0.00253	0.00582	CcSEcCtD
Paroxetine—Eructation—Cyclosporine—focal segmental glomerulosclerosis	0.00249	0.00571	CcSEcCtD
Paroxetine—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00249	0.00571	CcSEcCtD
Paroxetine—Urinary incontinence—Cyclosporine—focal segmental glomerulosclerosis	0.00244	0.00562	CcSEcCtD
Paroxetine—Nightmare—Cyclosporine—focal segmental glomerulosclerosis	0.00244	0.00562	CcSEcCtD
Paroxetine—Candida infection—Cyclosporine—focal segmental glomerulosclerosis	0.00242	0.00555	CcSEcCtD
Paroxetine—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.0024	0.00552	CcSEcCtD
Paroxetine—Blood urea increased—Cyclosporine—focal segmental glomerulosclerosis	0.00239	0.00549	CcSEcCtD
Paroxetine—Neuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00238	0.00546	CcSEcCtD
Paroxetine—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.00231	0.00531	CcSEcCtD
Paroxetine—Coma—Cyclosporine—focal segmental glomerulosclerosis	0.00231	0.00531	CcSEcCtD
Paroxetine—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.00229	0.00526	CcSEcCtD
Paroxetine—Urine output increased—Cyclosporine—focal segmental glomerulosclerosis	0.00229	0.00526	CcSEcCtD
Paroxetine—Abnormal vision—Cyclosporine—focal segmental glomerulosclerosis	0.00221	0.00507	CcSEcCtD
Paroxetine—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.0022	0.00505	CcSEcCtD
Paroxetine—Mental disability—Cyclosporine—focal segmental glomerulosclerosis	0.0022	0.00505	CcSEcCtD
Paroxetine—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00215	0.00495	CcSEcCtD
Paroxetine—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00211	0.00485	CcSEcCtD
Paroxetine—Hepatic function abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.0021	0.00483	CcSEcCtD
Paroxetine—Polyuria—Cyclosporine—focal segmental glomerulosclerosis	0.00209	0.00481	CcSEcCtD
Paroxetine—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.00207	0.00476	CcSEcCtD
Paroxetine—Deafness—Cyclosporine—focal segmental glomerulosclerosis	0.00205	0.00472	CcSEcCtD
Paroxetine—Vascular purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00205	0.00472	CcSEcCtD
Paroxetine—Disorientation—Cyclosporine—focal segmental glomerulosclerosis	0.00205	0.00472	CcSEcCtD
Paroxetine—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.00204	0.0047	CcSEcCtD
Paroxetine—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00204	0.0047	CcSEcCtD
Paroxetine—Eye pain—Cyclosporine—focal segmental glomerulosclerosis	0.00203	0.00468	CcSEcCtD
Paroxetine—Injury—Cyclosporine—focal segmental glomerulosclerosis	0.002	0.00459	CcSEcCtD
Paroxetine—Libido decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00198	0.00455	CcSEcCtD
Paroxetine—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00195	0.00449	CcSEcCtD
Paroxetine—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.00194	0.00445	CcSEcCtD
Paroxetine—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00193	0.00444	CcSEcCtD
Paroxetine—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.00192	0.00442	CcSEcCtD
Paroxetine—Purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00191	0.00438	CcSEcCtD
Paroxetine—Anaphylactoid reaction—Cyclosporine—focal segmental glomerulosclerosis	0.0019	0.00436	CcSEcCtD
Paroxetine—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00189	0.00434	CcSEcCtD
Paroxetine—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00188	0.00433	CcSEcCtD
Paroxetine—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00187	0.00431	CcSEcCtD
Paroxetine—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00184	0.00422	CcSEcCtD
Paroxetine—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.00182	0.00419	CcSEcCtD
Paroxetine—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.00181	0.00416	CcSEcCtD
Paroxetine—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.00181	0.00416	CcSEcCtD
Paroxetine—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.00174	0.004	CcSEcCtD
Paroxetine—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.00168	0.00387	CcSEcCtD
Paroxetine—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00166	0.00381	CcSEcCtD
Paroxetine—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.00165	0.0038	CcSEcCtD
Paroxetine—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.00163	0.00374	CcSEcCtD
Paroxetine—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.00162	0.00372	CcSEcCtD
Paroxetine—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.00159	0.00365	CcSEcCtD
Paroxetine—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00156	0.00358	CcSEcCtD
Paroxetine—Sweating increased—Cyclosporine—focal segmental glomerulosclerosis	0.00155	0.00355	CcSEcCtD
Paroxetine—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.00153	0.00351	CcSEcCtD
Paroxetine—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.00148	0.00341	CcSEcCtD
Paroxetine—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.00147	0.00337	CcSEcCtD
Paroxetine—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.00144	0.00332	CcSEcCtD
Paroxetine—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00144	0.0033	CcSEcCtD
Paroxetine—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00143	0.00329	CcSEcCtD
Paroxetine—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.00142	0.00327	CcSEcCtD
Paroxetine—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.00141	0.00324	CcSEcCtD
Paroxetine—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00139	0.00321	CcSEcCtD
Paroxetine—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.00139	0.00319	CcSEcCtD
Paroxetine—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.00139	0.00319	CcSEcCtD
Paroxetine—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00138	0.00317	CcSEcCtD
Paroxetine—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.00138	0.00317	CcSEcCtD
Paroxetine—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00138	0.00316	CcSEcCtD
Paroxetine—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00138	0.00316	CcSEcCtD
Paroxetine—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00135	0.0031	CcSEcCtD
Paroxetine—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00134	0.00308	CcSEcCtD
Paroxetine—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00133	0.00307	CcSEcCtD
Paroxetine—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00133	0.00305	CcSEcCtD
Paroxetine—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.00128	0.00294	CcSEcCtD
Paroxetine—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.00293	CcSEcCtD
Paroxetine—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.00292	CcSEcCtD
Paroxetine—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.00292	CcSEcCtD
Paroxetine—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.00291	CcSEcCtD
Paroxetine—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.0029	CcSEcCtD
Paroxetine—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00125	0.00287	CcSEcCtD
Paroxetine—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00122	0.00281	CcSEcCtD
Paroxetine—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.00118	0.00272	CcSEcCtD
Paroxetine—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.00118	0.00271	CcSEcCtD
Paroxetine—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00115	0.00265	CcSEcCtD
Paroxetine—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.00263	CcSEcCtD
Paroxetine—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.00262	CcSEcCtD
Paroxetine—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.00113	0.00261	CcSEcCtD
Paroxetine—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.00112	0.00258	CcSEcCtD
Paroxetine—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.00256	CcSEcCtD
Paroxetine—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.00254	CcSEcCtD
Paroxetine—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00109	0.00251	CcSEcCtD
Paroxetine—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.00109	0.00249	CcSEcCtD
Paroxetine—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.00249	CcSEcCtD
Paroxetine—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00107	0.00247	CcSEcCtD
Paroxetine—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.00106	0.00244	CcSEcCtD
Paroxetine—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.00104	0.0024	CcSEcCtD
Paroxetine—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00104	0.00238	CcSEcCtD
Paroxetine—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00103	0.00236	CcSEcCtD
Paroxetine—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00102	0.00235	CcSEcCtD
Paroxetine—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.00102	0.00234	CcSEcCtD
Paroxetine—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.00101	0.00232	CcSEcCtD
Paroxetine—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000997	0.00229	CcSEcCtD
Paroxetine—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.000994	0.00228	CcSEcCtD
Paroxetine—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00099	0.00228	CcSEcCtD
Paroxetine—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000965	0.00222	CcSEcCtD
Paroxetine—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.000958	0.0022	CcSEcCtD
Paroxetine—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000955	0.00219	CcSEcCtD
Paroxetine—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000941	0.00216	CcSEcCtD
Paroxetine—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000941	0.00216	CcSEcCtD
Paroxetine—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000941	0.00216	CcSEcCtD
Paroxetine—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000938	0.00216	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000935	0.00215	CcSEcCtD
Paroxetine—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00093	0.00214	CcSEcCtD
Paroxetine—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000921	0.00212	CcSEcCtD
Paroxetine—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.00091	0.00209	CcSEcCtD
Paroxetine—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.000903	0.00207	CcSEcCtD
Paroxetine—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000903	0.00207	CcSEcCtD
Paroxetine—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000897	0.00206	CcSEcCtD
Paroxetine—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000885	0.00203	CcSEcCtD
Paroxetine—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000884	0.00203	CcSEcCtD
Paroxetine—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000877	0.00202	CcSEcCtD
Paroxetine—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000872	0.00201	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000822	0.00189	CcSEcCtD
Paroxetine—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000816	0.00188	CcSEcCtD
Paroxetine—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00081	0.00186	CcSEcCtD
Paroxetine—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000805	0.00185	CcSEcCtD
Paroxetine—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.000802	0.00184	CcSEcCtD
Paroxetine—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000794	0.00183	CcSEcCtD
Paroxetine—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000785	0.0018	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000779	0.00179	CcSEcCtD
Paroxetine—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000778	0.00179	CcSEcCtD
Paroxetine—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000772	0.00177	CcSEcCtD
Paroxetine—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000772	0.00177	CcSEcCtD
Paroxetine—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000744	0.00171	CcSEcCtD
Paroxetine—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000738	0.0017	CcSEcCtD
Paroxetine—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000717	0.00165	CcSEcCtD
Paroxetine—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000713	0.00164	CcSEcCtD
Paroxetine—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000713	0.00164	CcSEcCtD
Paroxetine—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000665	0.00153	CcSEcCtD
Paroxetine—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000648	0.00149	CcSEcCtD
Paroxetine—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000639	0.00147	CcSEcCtD
Paroxetine—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000618	0.00142	CcSEcCtD
Paroxetine—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000597	0.00137	CcSEcCtD
Paroxetine—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000574	0.00132	CcSEcCtD
Paroxetine—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000569	0.00131	CcSEcCtD
Paroxetine—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000569	0.00131	CcSEcCtD
Paroxetine—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000565	0.0013	CcSEcCtD
Paroxetine—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000536	0.00123	CcSEcCtD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000129	0.00157	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000128	0.00156	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000127	0.00155	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000126	0.00154	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000126	0.00153	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000125	0.00152	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000123	0.0015	CbGpPWpGaD
Paroxetine—SLC6A3—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.000121	0.00147	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000121	0.00147	CbGpPWpGaD
Paroxetine—SLC6A3—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	0.00012	0.00146	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.00012	0.00146	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.00012	0.00146	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000118	0.00144	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—SERPINE1—focal segmental glomerulosclerosis	0.000116	0.00142	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000115	0.00141	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000115	0.0014	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000115	0.0014	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000114	0.00139	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000114	0.00139	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000114	0.00138	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000113	0.00138	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000113	0.00138	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000112	0.00137	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000109	0.00133	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000109	0.00133	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000109	0.00132	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000108	0.00132	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000107	0.0013	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000106	0.00129	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000106	0.00129	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000105	0.00128	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000105	0.00128	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000104	0.00127	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000101	0.00123	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	9.8e-05	0.00119	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	9.79e-05	0.00119	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	9.74e-05	0.00119	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	9.71e-05	0.00118	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	9.63e-05	0.00117	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	9.61e-05	0.00117	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	9.56e-05	0.00116	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	9.53e-05	0.00116	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	9.25e-05	0.00113	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	9.22e-05	0.00112	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	9.18e-05	0.00112	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	9.15e-05	0.00111	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	9.15e-05	0.00111	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	8.79e-05	0.00107	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	8.76e-05	0.00107	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	8.74e-05	0.00106	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	8.53e-05	0.00104	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	8.49e-05	0.00103	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	8.49e-05	0.00103	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	8.46e-05	0.00103	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	8.44e-05	0.00103	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	8.41e-05	0.00102	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	8.38e-05	0.00102	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	8.37e-05	0.00102	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	8.33e-05	0.00101	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	8.16e-05	0.000994	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	8.13e-05	0.000989	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	8.08e-05	0.000984	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	8.06e-05	0.000981	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	8.05e-05	0.000981	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	8.02e-05	0.000976	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	7.98e-05	0.000971	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	7.98e-05	0.000971	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	7.95e-05	0.000968	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	7.91e-05	0.000964	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	7.87e-05	0.000959	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	7.81e-05	0.000952	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	7.75e-05	0.000944	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	7.71e-05	0.000939	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	7.71e-05	0.000938	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	7.68e-05	0.000936	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	7.66e-05	0.000933	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	7.64e-05	0.00093	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	7.61e-05	0.000927	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	7.57e-05	0.000921	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	7.45e-05	0.000907	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	7.41e-05	0.000902	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	7.37e-05	0.000897	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	7.35e-05	0.000895	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	7.33e-05	0.000892	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	7.31e-05	0.00089	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	7.31e-05	0.00089	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	7.23e-05	0.000881	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	7.13e-05	0.000869	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	7.1e-05	0.000864	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	7.1e-05	0.000864	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	7.07e-05	0.000861	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	7e-05	0.000853	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	6.9e-05	0.00084	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	6.77e-05	0.000825	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	6.75e-05	0.000822	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	6.71e-05	0.000818	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	6.56e-05	0.000798	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	6.53e-05	0.000795	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	6.49e-05	0.00079	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	6.49e-05	0.00079	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	6.48e-05	0.000789	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	6.47e-05	0.000788	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	6.47e-05	0.000787	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	6.44e-05	0.000785	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	6.43e-05	0.000783	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	6.42e-05	0.000782	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	6.41e-05	0.00078	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	6.36e-05	0.000775	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	6.23e-05	0.000758	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	6.19e-05	0.000754	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	6.17e-05	0.000752	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	6.15e-05	0.000749	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	6.11e-05	0.000744	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	6.11e-05	0.000744	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	6.08e-05	0.000741	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	5.93e-05	0.000721	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	5.89e-05	0.000718	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	5.89e-05	0.000717	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	5.87e-05	0.000715	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	5.82e-05	0.000708	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	5.65e-05	0.000687	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—LIPC—focal segmental glomerulosclerosis	5.59e-05	0.000681	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	5.58e-05	0.00068	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	5.53e-05	0.000674	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	5.5e-05	0.00067	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	5.48e-05	0.000668	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	5.43e-05	0.000661	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	5.41e-05	0.000658	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	5.16e-05	0.000629	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	5.02e-05	0.000612	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	5e-05	0.000608	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	4.98e-05	0.000606	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	4.94e-05	0.000602	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	4.93e-05	0.000601	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CTGF—focal segmental glomerulosclerosis	4.93e-05	0.0006	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	4.84e-05	0.000589	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—LIPC—focal segmental glomerulosclerosis	4.81e-05	0.000586	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	4.78e-05	0.000582	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	4.66e-05	0.000567	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	4.59e-05	0.000559	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	4.58e-05	0.000557	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	4.57e-05	0.000556	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	4.55e-05	0.000554	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	4.55e-05	0.000554	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	4.55e-05	0.000554	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	4.54e-05	0.000553	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	4.54e-05	0.000553	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.54e-05	0.000553	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	4.53e-05	0.000551	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	4.51e-05	0.00055	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	4.51e-05	0.000549	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	4.5e-05	0.000547	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	4.47e-05	0.000544	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	4.38e-05	0.000533	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—LPL—focal segmental glomerulosclerosis	4.25e-05	0.000517	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CTGF—focal segmental glomerulosclerosis	4.24e-05	0.000516	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	4.19e-05	0.00051	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	4.17e-05	0.000508	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	4.15e-05	0.000505	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	4.13e-05	0.000503	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	4.09e-05	0.000498	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—LIPC—focal segmental glomerulosclerosis	4.07e-05	0.000496	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—LPL—focal segmental glomerulosclerosis	4.07e-05	0.000495	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	4.02e-05	0.00049	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.9e-05	0.000475	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	3.89e-05	0.000473	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.85e-05	0.000469	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.84e-05	0.000468	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.83e-05	0.000466	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.81e-05	0.000464	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.79e-05	0.000462	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.76e-05	0.000458	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	3.67e-05	0.000446	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.63e-05	0.000442	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CTGF—focal segmental glomerulosclerosis	3.59e-05	0.000437	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	3.55e-05	0.000432	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.5e-05	0.000426	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.48e-05	0.000424	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.48e-05	0.000424	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.47e-05	0.000423	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.44e-05	0.000418	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—LPL—focal segmental glomerulosclerosis	3.41e-05	0.000416	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.36e-05	0.000409	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	3.35e-05	0.000407	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—LIPC—focal segmental glomerulosclerosis	3.32e-05	0.000404	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.31e-05	0.000402	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.22e-05	0.000391	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	3.13e-05	0.000381	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	3.04e-05	0.00037	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.98e-05	0.000363	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.97e-05	0.000361	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.95e-05	0.000359	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	2.95e-05	0.000359	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.94e-05	0.000358	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—LPL—focal segmental glomerulosclerosis	2.94e-05	0.000358	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AGT—focal segmental glomerulosclerosis	2.92e-05	0.000356	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CTGF—focal segmental glomerulosclerosis	2.92e-05	0.000355	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.91e-05	0.000355	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.88e-05	0.000351	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.88e-05	0.000351	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.86e-05	0.000349	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.85e-05	0.000348	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.83e-05	0.000344	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.79e-05	0.00034	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.73e-05	0.000332	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.71e-05	0.00033	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.71e-05	0.00033	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.7e-05	0.000329	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.69e-05	0.000328	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.68e-05	0.000326	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.68e-05	0.000326	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AGT—focal segmental glomerulosclerosis	2.51e-05	0.000306	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—LPL—focal segmental glomerulosclerosis	2.49e-05	0.000303	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.46e-05	0.0003	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.45e-05	0.000298	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.44e-05	0.000297	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.42e-05	0.000294	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.28e-05	0.000277	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.26e-05	0.000276	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.26e-05	0.000275	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ALB—focal segmental glomerulosclerosis	2.24e-05	0.000273	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.23e-05	0.000272	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	2.17e-05	0.000264	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.14e-05	0.000261	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AGT—focal segmental glomerulosclerosis	2.13e-05	0.000259	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.05e-05	0.00025	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	2.04e-05	0.000249	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—LPL—focal segmental glomerulosclerosis	2.02e-05	0.000246	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ALB—focal segmental glomerulosclerosis	1.93e-05	0.000235	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.89e-05	0.000231	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.88e-05	0.000229	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.88e-05	0.000229	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.86e-05	0.000226	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	1.85e-05	0.000226	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.76e-05	0.000215	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	1.75e-05	0.000213	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AGT—focal segmental glomerulosclerosis	1.73e-05	0.000211	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.69e-05	0.000206	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ALB—focal segmental glomerulosclerosis	1.63e-05	0.000199	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.45e-05	0.000177	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.44e-05	0.000176	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.44e-05	0.000175	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.42e-05	0.000173	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	1.42e-05	0.000173	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	1.34e-05	0.000163	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ALB—focal segmental glomerulosclerosis	1.33e-05	0.000162	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.2e-05	0.000146	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.19e-05	0.000145	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.19e-05	0.000144	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.17e-05	0.000143	CbGpPWpGaD
